Abstract:Background: Acute lung injury caused by renal ischemia-reperfusion is one of the leading causes of acute kidney injury-related death. Dexmedetomidine, an alpha(2)-adrenergic agonist sedative, has been found to have protective effects against acute kidney injury and remote lung injury. We sought to determine whether dexmedetomidine can exert its anti-apoptotic effects in acute lung injury after acute kidney injury, in addition to its common anti-inflammatory effects, and to determine the underlying mechanisms.Methods: In vivo, acute kidney injury was induced by 60 min of kidney ischemia (bilateral occlusion of renal pedicles) followed by 24 h of reperfusion. Mice received dexmedetomidine (25 mu g/kg, i.p.) in the absence or presence of alpha(2)-adrenergic antagonist atipamezole (250 mu g/kg, i.p.) before IR. Histological assessment of the lung was conducted by HE staining and arterial blood gases were measured. Lung apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay. The expression of caspase 3 and p-Akt in lung tissue was detected by western blot. In vitro, C57BL/6J mice pulmonary microvascular endothelial cells were treated with serum from mice obtained following sham or IR. Dexmedetomidine was given before serum stimulation in cells, alone or with atipamezole or LY294002. Cell viability was assessed by CCK 8 assay. Cell apoptosis was examined by Hoechst staining and Annexin V-FITC/PI staining flow cytometry analysis. Mitochondrial membrane potential was measured by flow cytometry. The expression of p-Akt, caspase 3, Bcl-2 and Bax was measured by western blot.Results: In vivo, dexmedetomidine remarkably mitigated pathohistological changes and apoptosis and significantly increased p-Akt expression in the lung. In addition, dexmedetomidine also slightly improved oxygenation in mice after IR, which can be abolished by atipamezole. In vitro, dexmedetomidine significantly inhibited IR serum-induced loss of viability and apoptosis in PMVECs. Dexmedetomidine increased p-Akt in a time-and dose-dependent manner, and down-regulated the expression of caspase 3 and Bax and up-regulated the Bcl-2 expression in PMVECs. The changes of MMP were also improved by dexmedetomidine. Whilst these effects were abolished by Atipamezole or LY294002.Conclusion: Our results demonstrated that dexmedetomidine attenuates lung apoptosis induced by IR, at least in part, via alpha(2)AR/PI3K/Akt pathway.

Dexmedetomidine Attenuates Lung Ischemia-reperfusion Injury in Rats by Reducing Mitochondrial Dysfunction

Pretreatment with dexmedetomidine alleviates lung injury in a rat model of intestinal ischemia reperfusion

Dexmedetomidine Attenuates Lung Apoptosis Induced By Renal Ischemiareperfusion Injury Through Alpha(2)Ar/Pi3k/Akt Pathway

Effect of Dexmedetomidine Pretreatment on Lung Injury Following Intestinal Ischemia-Reperfusion

Dexmedetomidine Attenuates Renal and Myocardial Ischemia/Reperfusion Injury in a Dose-Dependent Manner by Inhibiting Inflammatory Response.

Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway

Dexmedetomidine attenuates lung apoptosis induced by renal ischemia–reperfusion injury through α 2 AR/PI3K/Akt pathway

The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury

Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming

Dexmedetomidine Attenuates Myocardial Ischemia-Reperfusion Injury in Hyperlipidemic Rats by Inhibiting Inflammation, Oxidative Stress and NF-B

Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway

Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats.

Dexmedetomidine Preconditioning Inhibits the Long Term Inflammation Induced by Renal Ischemia/reperfusion Injury in Rats.

Dexmedetomidine Protects Intestinal Ischemia-Reperfusion Injury Via Inhibiting P38 MAPK Cascades.

Effect of dexmedetomidine on myocardial ischemia-reperfusion injury in rats

Dexmedetomidine Pretreatment Reduces Myocardial Ischemia And Reperfusion Injury In Rats By Altering Jak/Stat And Pi3k/Akt Levels

Dexmedetomidine Attenuates Ischemia/Reperfusion-Induced Myocardial Inflammation and Apoptosis Through Inhibiting Endoplasmic Reticulum Stress Signaling

Dexmedetomidine Reduces Enteric Glial Cell Injury Induced by Intestinal Ischaemia-Reperfusion Injury Through Mitochondrial Localization of TERT.

The Protective Mechanism of Dexmedetomidine in Regulating Atg14L-Beclin1-Vps34 Complex Against Myocardial Ischemia-Reperfusion Injury

Dexmedetomidine Alleviates Brain Ischemia/Reperfusion Injury by Regulating Metastasis-associated Lung Adenocarcinoma Transcript 1/MicroRNA-140-5p/ Nuclear Factor Erythroid-derived 2-like 2 Axis

Dexmedetomidine alleviates Hypoxia/reoxygenation-induced mitochondrial dysfunction in cardiomyocytes via activation of Sirt3/Prdx3 pathway